

Please Direct All Correspondence to Customer Number **20995****TRANSMITTAL LETTER  
INFORMATION DISCLOSURE STATEMENT**

Applicant : Ketelslegers, et al.  
App. No : 10/593,372  
Filed : September 19, 2006  
For : PROGNOSTIC METHODS FOR  
CONGESTIVE HEART FAILURE  
Examiner : Unknown  
Art Unit : Unknown

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

December 22, 2006

(Date)

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing and enclosing 8 references for consideration.
- (X) Return prepaid postcard.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

**INFORMATION DISCLOSURE STATEMENT**

Applicant : Ketelslegers, et al.  
App. No : 10/593,372  
Filed : September 19, 2006  
For : PROGNOSTIC METHODS FOR  
CONGESTIVE HEART FAILURE  
Examiner : Unknown  
Art Unit : Unknown

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 8 references to be considered by the Examiner. Eight references are provided herewith.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Dec. 22, 2006

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/593,372
Filing Date	September 19, 2006
First Named Inventor	Ketelslegers, et al.
Art Unit	<del>Unknown</del> 1641
Examiner	<del>Unknown</del> J. Grun
Attorney Docket No.	DECLE129.001APC

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
/JLG/		Rousseau, et al. "Endothelial Markers Big Endothelin-1 and Endothelin-1 are Better than Natriuretic Peptides to Predict Survival in Severe Congestive Heart Failure," <i>Circulation</i> , Vol. 108, No. 17 Supplement, page IV-556, October 28, 2003.	
↓		Selvais, et al. "Direct Comparison Between Endothelin-1, N-Terminal Proatrial Natriuretic Factor, and Brain Natriuretic Peptide as Prognostic Markers of Survival in Congestive Heart Failure," <i>Journal of Cardiac Failure</i> , Vol. 6, No. 3, pp. 201-207, September, 2000	
↓		Berger, et al. "Prognostic Power of Neurohumoral Parameters in Chronic Heart Failure Depends on Clinical Stage and Observation Period," <i>The Journal of Heart and Lung Transplantation</i> , Vol. 22, No. 9, pp. 1037-1045, September, 2003.	
↓		Selvais, et al. "Cardiac Natriuretic Peptides for Diagnosis and Risk Stratification in Heart Failure: Influences of Left Ventricular Dysfunction and Coronary Artery Disease on Cardiac Hormonal Activation," <i>European Journal of Clinical Investigation</i> , Vol. 28, No. 8, pp. 636-642, August, 1998.	
↓		Valdemarsson, et al. "Relationships Between Plasma Levels of Catecholamines and Neuropeptides and the Survival Time in Patients with Congestive Heart Failure," <i>Journal of Internal Medicine</i> , Vol. 235, No. 6, pp. 595-601, June, 1994.	
↓		Ruskoaho, Heikki. "Cardiac Hormones as Diagnostic Tools in Heart Failure," <i>Endocrine Reviews</i> , Vol. 24, No. 3, pp. 341-356, June, 2003.	
↓		Stanek, et al. "Validation of Big Endothelin Plasma Levels Compared with Established Neurohumoral Markers in Patients with Severe Chronic Heart Failure," <i>Transplantation Proceedings</i> , Vol. 29, No. 1-2, pp. 595-596, February, 1997.	
/JLG/		Hülsmann, et al. "Value of Cardiopulmonary Exercise Testing and Big Endothelin Plasma Levels to Predict Short-Term Prognosis of Patients with Chronic Heart Failure," <i>Journal of the American College of Cardiology</i> , Vol. 32, No. 6, pp. 1695-1700, November 15, 1998.	

3241992  
122206

Examiner Signature	/James L. Grun/	Date Considered	09/22/2009
--------------------	-----------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.